Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib plus Pembrolizumab in Selected Solid Tumors
NCT02501096Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jul 2015
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of lenvatinib in non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial carcinoma, urothelial carcinoma (UC), squamous cell carcinoma of the head and neck (HNSCC), sponsored by Eisai Co., Ltd.. Started Jul 2015; status: completed.
02
Drugs
lenvatinib
03
Conditions
non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)endometrial carcinomaurothelial carcinoma (UC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT02501096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02501096.